COMMUNIQUÉS West-GlobeNewswire

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
25/03/2026
Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in [...]
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
25/03/2026
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund [...]
Lifeward Successfully Closes on Strategic Partnership with Oramed
25/03/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people [...]
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
25/03/2026
GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune [...]
Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
25/03/2026
Application to upgrade market tier approved WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
25/03/2026
- FDA Grants IND Clearance for SER-252 - SER-252 Phase 1b Trial Initiated - Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or [...]
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
25/03/2026
Reverse Split Expected to Take Effect March 30, 2026 HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued [...]
BeyondSpring Files 2025 Annual Report on Form 10-K
25/03/2026
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and [...]
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
25/03/2026
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product sales Expanded [...]
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
25/03/2026
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
Financière de Tubize - Convocation des actionnaires à l’Assemblée Générale Ordinaire du 24 avril 2026
25/03/2026
Convocation des actionnaires à l’Assemblée Générale Ordinaire du 24 avril 2026 Les actionnaires sont invités à prendre part à l’assemblée générale ordinaire qui se tiendra le 24 avril 2026 à 11 heures à 1070 Bruxelles ( [...]
CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier
25/03/2026
DIJON, France – 25 mars 2026 (18H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie [...]
CROSSJECT appoints Lionel Seltz as Chief Financial Officer
25/03/2026
DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® needle-free auto- [...]
Financière de Tubize - Convening of the ordinary general meetings of shareholders of April 24, 2026
25/03/2026
Convening of the Ordinary Meeting of shareholders of 24 April 2026 The shareholders are invited to attend the ordinary general meeting, which will take place on Friday 24th of April 2026 at 11:00AM at 1070 Brussels ( [...]
Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration
25/03/2026
Realbotix Humanoid Robot — Ericsson’s First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson’s U.S. Headquarters; Onconetix Has Entered into a Definitive [...]
Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
25/03/2026
SPRING, Texas, March 25, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports – Nature , of [...]
Catalyst MedTech Establishes Full Access Neurology Solution as the Industry Standard for Brain PET Implementation in the U.S.
25/03/2026
Full Access Neurology is a proven, end-to-end optimized Brain PET clinical solution—built for real-world implementation PITTSBURGH, March 25, 2026 (GLOBE NEWSWIRE) -- Catalyst MedTech, a national leader in nuclear [...]

Pages